BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 16997145)

  • 1. Inhibitors of de novo folate enzymes in Plasmodium falciparum.
    Nzila A
    Drug Discov Today; 2006 Oct; 11(19-20):939-44. PubMed ID: 16997145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular epidemiology of malaria in Cameroon. XXVII. Clinical and parasitological response to sulfadoxine-pyrimethamine treatment and Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase alleles in Cameroonian children.
    Tahar R; Basco LK
    Acta Trop; 2007 Aug; 103(2):81-9. PubMed ID: 17640607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of resistance of malaria parasites to antifolates.
    Gregson A; Plowe CV
    Pharmacol Rev; 2005 Mar; 57(1):117-45. PubMed ID: 15734729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations in modification of Plasmodium falciparum characteristics.
    A-Elbasit IE; Alifrangis M; Khalil IF; Bygbjerg IC; Masuadi EM; Elbashir MI; Giha HA
    Malar J; 2007 Aug; 6():108. PubMed ID: 17686173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifolates can have a role in the treatment of Plasmodium vivax.
    Hawkins VN; Joshi H; Rungsihirunrat K; Na-Bangchang K; Sibley CH
    Trends Parasitol; 2007 May; 23(5):213-22. PubMed ID: 17368986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to Anopheles mosquitoes.
    Méndez F; Herrera S; Murrain B; Gutiérrez A; Moreno LA; Manzano M; Muñoz A; Plowe CV
    Am J Trop Med Hyg; 2007 Sep; 77(3):438-43. PubMed ID: 17827356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the folate pathway in Plasmodium falciparum.
    Hyde JE
    Acta Trop; 2005 Jun; 94(3):191-206. PubMed ID: 15845349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translational up-regulation of antifolate drug targets in the human malaria parasite Plasmodium falciparum upon challenge with inhibitors.
    Nirmalan N; Sims PF; Hyde JE
    Mol Biochem Parasitol; 2004 Jul; 136(1):63-70. PubMed ID: 15138068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elucidation of sulfadoxine resistance with structural models of the bifunctional Plasmodium falciparum dihydropterin pyrophosphokinase-dihydropteroate synthase.
    de Beer TA; Louw AI; Joubert F
    Bioorg Med Chem; 2006 Jul; 14(13):4433-43. PubMed ID: 16517168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfection studies to explore essential folate metabolism and antifolate drug synergy in the human malaria parasite Plasmodium falciparum.
    Wang P; Wang Q; Aspinall TV; Sims PF; Hyde JE
    Mol Microbiol; 2004 Mar; 51(5):1425-38. PubMed ID: 14982635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct haplotypes of dhfr and dhps among Plasmodium falciparum isolates in an area of high level of sulfadoxine-pyrimethamine (SP) resistance in eastern Sudan.
    Al-Saai S; Kheir A; Abdel-Muhsin AM; Al-Ghazali A; Nwakanma D; Swedberg G; Babiker HA
    Infect Genet Evol; 2009 Sep; 9(5):778-83. PubMed ID: 19379843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the optimal third generation antifolate against P. falciparum and P. vivax.
    Hunt SY; Detering C; Varani G; Jacobus DP; Schiehser GA; Shieh HM; Nevchas I; Terpinski J; Sibley CH
    Mol Biochem Parasitol; 2005 Dec; 144(2):198-205. PubMed ID: 16181688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basis for antifolate action and resistance in malaria.
    Yuthavong Y
    Microbes Infect; 2002 Feb; 4(2):175-82. PubMed ID: 11880049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2,4-diaminopteridine-based compounds as precursors for de novo synthesis of antifolates: a novel class of antimalarials.
    Nduati E; Hunt S; Kamau EM; Nzila A
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3652-7. PubMed ID: 16127035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folate metabolism in malaria.
    Ferone R
    Bull World Health Organ; 1977; 55(2-3):291-8. PubMed ID: 338184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The past, present and future of antifolates in the treatment of Plasmodium falciparum infection.
    Nzila A
    J Antimicrob Chemother; 2006 Jun; 57(6):1043-54. PubMed ID: 16617066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A rapid assay for dihydropteroate synthase activity suitable for identification of inhibitors.
    Fernley RT; Iliades P; Macreadie I
    Anal Biochem; 2007 Jan; 360(2):227-34. PubMed ID: 17134675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to sulphadrug-based antifolate therapy in malaria: are we looking in the right place?
    Platteeuw JJ
    Trop Med Int Health; 2006 Jun; 11(6):804-8. PubMed ID: 16772001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of Plasmodium falciparum to cotrimoxazole therapy: relationship with plasma drug concentrations and dihydrofolate reductase and dihydropteroate synthase genotypes.
    Khalil IF; Rønn AM; Alifrangis M; Gabar HA; Jelinek T; Satti GM; Bygbjerg IC
    Am J Trop Med Hyg; 2005 Jul; 73(1):174-7. PubMed ID: 16014854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase.
    Fogel GB; Cheung M; Pittman E; Hecht D
    J Mol Graph Model; 2008 Apr; 26(7):1145-52. PubMed ID: 18037315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.